Profound Medical Corp. reported a 104% year-over-year increase in revenue for the first quarter of 2026 [1].
The growth signals a scaling phase for the company's specialized medical technology. Increased revenue and expanded insurance coverage typically lower the barrier for patient access and drive higher adoption rates among healthcare providers.
Based in Toronto, Canada [2], the company released the financial results on May 7 [3]. The report included full-year 2026 revenue guidance and a significant update regarding the TULSA Procedure™, a specialized medical intervention developed by the firm.
Stephen, the CEO of Profound Medical, highlighted the company's recent performance during an earnings call. "We delivered a record 104% year-over-year revenue growth in the first quarter," Stephen said [4].
Beyond the financial figures, the company announced a strategic expansion in payer coverage. According to a press release, Humana is now covering the TULSA Procedure™ [5]. This addition to the list of insurance providers is expected to influence the company's trajectory for the remainder of the fiscal year.
The company is listed on both the NASDAQ under the symbol PROF and the TSX under PRN [6]. The announcement of the results followed a previously scheduled timeline, with the company having alerted investors in April that the May 7 disclosure would be accompanied by a conference call [7].
“We delivered a record 104% year-over-year revenue growth in the first quarter.”
The combination of triple-digit revenue growth and the addition of Humana to its payer network suggests that Profound Medical is transitioning from a niche technology provider to a more broadly accepted clinical standard. Insurance coverage is often the primary catalyst for volume growth in medical device adoption, as it removes the financial burden from patients and simplifies the billing process for hospitals.
